Professor Thomas Thum, MD, PhD, is Director of the Institute of Molecular and Translational Therapeutic Strategies at Hannover Medical School and Visiting Professor at Imperial College London. His research focuses on cardiovascular medicine, fibrosis and the development of RNA-based therapeutics, spanning target discovery through clinical translation. He has authored more
Tran Trang graduated with a PhD in Life Science in 2011 at the University of Burgundy and has broad experience from in vitro target discovery up to preclinical candidate selection in metabolism and immuno-inflammation area. During her postdoc at Sanofi, she worked on anti-PCSK9 antibody (Praluent), an efficient cholesterol-lowering agent
Olivier is an accomplished antibody engineer with more than 30-year experience having worked for biotech (MRC collaborative centre and NovImmune) and pharma companies (Pierre Fabre, Merck Serono and Vetoquinol). Co-inventor of three marketed therapeutic antibodies, Tysarbri, Bavencio and Gamifant. Co-founder of the technology company Deeptope. Olivier has expertise in antibody
Régis brings more than 25 years of experience in the areas of finance, structuring and management of health technology companies. Prior to joining Tridek-One, Régis was CEO of Axess Vision Technology, a company dedicated to the development of single-use medical endoscopes, where he led the launch of new products and
Mariangela holds a double degree Ph.D. in Life Science /Experimental Medicine, Innovative technologies in translational medicine from Université d’Artois (France) and Sapienza University of Rome (Italy). She performed a postdoc at “Institut de la Vision” in Metabolic and redox signalling in the brain as a post-doc before joining Tridek-One in 2022
Delia obtained her double PhD degree in Life Sciences/ Biomedicine from Maastricht University (The Netherlands) and the University of Santiago de Compostela (Spain) as part of an Innovative Training Network EU H2020 consortium. During her PhD, she investigated small molecule inhibitors for platelet adhesion receptors in thrombosis. She joined Tridek-One
Jean-François has been working in the field of immunology for 30-yr + including 20 years for several biotech and pharmaceutical companies (Serono Pharmaceutical, Merck Serono SA, Merck KGaA, Fresenius-Kabi, and GeNeuro SA). He has expertise in the development of biologics for FiM readiness including selection of PoC studies to serve autoimmune,
Giuseppina has a longstanding research experience in the role of CD31 in vascular biology and immunology. She works both as a cardiologist and a research scientist at the University Hospital Bichat, in Paris. Giuseppina completed her medical studies at the Catholic University of Rome, obtained a PhD in experimental medicine
Professor and head of the doctoral school in Immunology at the University Paris Cité, Antonino leads the Laboratory for Vascular Translational Science, INSERM U1148, in Paris. Antonino Nicoletti obtained a PhD on inflammation in hypertension in Paris and performed a postdoc at the Karolinska Institute in Stockholm where he demonstrated